Login to Your Account



Gilead Adds To Fibrotic Disease Pipeline In $202M Deal With LGLS

By Jennifer Boggs


Thursday, November 8, 2007
Gilead Sciences Inc. is paying Korean firm LG Life Sciences Ltd. $20 million up front for rights to a caspase inhibitor program for fibrotic diseases, which includes a Phase II-stage compound being tested in patients with hepatitis C virus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription